Data protection Impressum

Oncology

Scientists at the University of Fribourg have identified a molecular mechanism that keeps certain breast cancer cells dormant by stimulating the immune response, opening new therapeutic perspectives.

Fribourg researchers identify breast cancer dormancy mechanism

11 February 2026

Inselspital Bern has performed its 300th CAR-T cell therapy treatment, underscoring Western Switzerland’s role as a leading center for advanced immuno-oncology.

Bern’s Inselspital marks a new era in personalized cancer treatment

8 December 2025

Researchers at CHUV have validated a new stem-cell–based method to study autoimmune diseases in organs such as the brain, offering new insights into conditions like autoimmune encephalitis and multiple sclerosis.

CHUV researchers develop new method to study autoimmune diseases

2 December 2025

A Swiss-led research consortium is developing an AI-powered microfactory capable of producing patient-specific tumor models to revolutionize precision oncology.

ORION: A smart microfactory to accelerate personalized cancer treatments

10 November 2025

Top Stories Western Switzerland

Top Stories from Western Switzerland (October 2025)

29 October 2025

The Munich- and Lausanne-based biotech secures Europe’s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.

Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline

29 October 2025

Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.

ADC Therapeutics raises USD 60 million to strengthen oncology portfolio

21 October 2025

A CHF 2.1 million endowed professorship will strengthen data-driven cancer medicine at the University of Bern and Inselspital.

New endowed professorship to advance digital cancer medicine in Bern

13 October 2025

Researchers from HUG and UNIGE have developed patient-derived lung cancer “mini-tumors” to rapidly identify the most effective personalized treatments.

Geneva team develops lung cancer “mini-tumors” to accelerate personalized treatments

13 August 2025

Two start-ups from Western Switzerland’s Health Valley, AzureCell Therapies and Myriad Optics, have each been awarded CHF 150,000 through the Gebert Rüf Stiftung’s Innobooster programme, which supports high-potential projects emerging from Swiss universities.

AzureCell Therapies and Myriad Optics awarded by Gebert Rüf Stiftung’s Innobooster programme

11 August 2025

1 2 3 4 5 … 10